Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects
NCT02297594 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- June 30, 2015
- Enrollment
- 74 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.